Zobrazeno 1 - 10
of 269
pro vyhledávání: '"Elcatonin"'
Publikováno v:
Journal of Pain Research, Vol Volume 12, Pp 223-230 (2019)
Yoshinori Terashima,1,2 Tsuneo Takebayashi,3 Shunsuke Jimbo,1 Izaya Ogon,1 Tatsuya Sato,2 Nobutoshi Ichise,2 Noritsugu Tohse,2 Toshihiko Yamashita1 1Department of Orthopaedic Surgery, School of Medicine, Sapporo Medical University, Sapporo 060-0061,
Externí odkaz:
https://doaj.org/article/65ee2103d3834f0da48cef1c9723039f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tsukasa Kanchiku, Yasuaki Imajo, Hidenori Suzuki, Yuichiro Yoshida, Toshihiko Taguchi, Toshikatsu Tominaga, Koichiro Toyoda
Publikováno v:
Asian Spine Journal, Vol 8, Iss 4, Pp 469-475 (2014)
Study DesignMulticenter prospective study with a crossover design.PurposeThe objective of this study is to compare the efficacy of limaprost alfadex (LP) and elcatonin (EL) for lumbar spinal stenosis (LSS) patients with concurrent osteoporosis.Overvi
Externí odkaz:
https://doaj.org/article/7edeecff9f4f43b1b89a09a98c479228
Autor:
Takenobu Yamamoto, Yumi Aoyama, Tetsuko Sato, Ryo Tanaka, Wataru Fujimoto, Nobuhiko Kamitani, Yoshihisa Wada
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 13, Iss 3, Pp 1209-1214 (2020)
Case Reports in Oncology, Vol 13, Iss 3, Pp 1209-1214 (2020)
Hypercalcemia of malignancy occurs in up to one third of patients at some point during the course of their advanced stage. The majority of them is caused by humoral hypercalcemia of malignancy due to systemic secretion of parathyroid hormone–relate
Publikováno v:
Osteoporosis and Sarcopenia, Vol 6, Iss 1, Pp 15-19 (2020)
Osteoporosis and Sarcopenia
Osteoporosis and Sarcopenia
Objectives: On July 20, 2012, the European Medicines Agency (EMA) provided a recommendation that limits the long-term use of calcitonin. Based on this recommendation, we investigate the presence or absence of a cancer diagnosis in subjects who partic
Publikováno v:
Drug Target Insights, Vol 2, Pp 55-60 (2007)
Bone morphogenetic protein (BMP) appears to be one of the most promising cytokine and for clinical use in reconstructive surgery for bony defects and augmentation. To evaluate the effect of basic fibroblast growth factor (bFGF), FK506, elcatonin, and
Externí odkaz:
https://doaj.org/article/c18d6392e364482a9f6cd443204df002
Publikováno v:
Osteoporosis International. 30:1723-1732
The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination therapies of elcatonin
Autor:
Nobutoshi Ichise, Izaya Ogon, Tsuneo Takebayashi, Yoshinori Terashima, Shunsuke Jimbo, Toshihiko Yamashita, Noritsugu Tohse, Tatsuya Sato
Publikováno v:
Journal of Pain Research
Yoshinori Terashima,1,2 Tsuneo Takebayashi,3 Shunsuke Jimbo,1 Izaya Ogon,1 Tatsuya Sato,2 Nobutoshi Ichise,2 Noritsugu Tohse,2 Toshihiko Yamashita1 1Department of Orthopaedic Surgery, School of Medicine, Sapporo Medical University, Sapporo 060-0061,
Autor:
Takami Miki, Masao Fukunaga, Hiroshi Hagino, Shinobu Akachi, Tetsuo Nakano, Masako Ito, Toshitaka Nakamura, Yoshiki Nishizawa, Toshitsugu Sugimoto, Hideaki Kishimoto, Teruki Sone, Masataka Shiraki
Publikováno v:
Current Medical Research and Opinion. 35:447-454
Very few reports have described changes in bone mineral density (BMD) with long-term, once weekly administration of elcatonin, and its effects in reducing incident fractures remain unverified. Therefore, the efficacy and safety of once weekly elcaton